2026-2034年全球霍亂疫苗市場規模、佔有率、趨勢和成長分析報告

霍亂疫苗市場預計將從 2025 年的 1.1036 億美元成長到 2034 年的 2.762 億美元，2026 年至 2034 年的複合年成長率為 10.73%。

隨著公共衛生部門將疾病控制和提高全球疫苗接種率列為優先事項，霍亂疫苗市場也不斷發展。未來的疫苗可望利用新型口服製劑、耐熱遞送系統和最佳化的佐劑，以提高免疫抗原性、延長保存期限並便於在偏遠地區部署。與數位化免疫追蹤平台的整合將有助於有效監測疫苗接種率和控制疫情爆發。

重組載體疫苗和合成胜肽製劑等新興技術可望縮短生產週期並擴大株覆蓋範圍。人工智慧驅動的流行病學模型指導策略性疫苗宣傳活動，最佳化資源分配並降低疾病發生率。行動醫療系統透過提高疫苗認知度、最佳化疫苗接種計畫管理以及追蹤本地接種依從性，為公共衛生基礎設施提供支援。

未來的成長將得益於旨在預防水傳播感染疾病、改善供應鏈物流和支持大規模免疫政策的國際措施。透過結合創新疫苗技術、數位健康整合和積極主動的疫情管理，霍亂疫苗將在減輕全球疾病負擔和增強公共衛生韌性方面發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球霍亂疫苗市場：按類型分類

• 市場分析、洞察與預測
• 重組B次單元全細胞霍亂弧菌O1型疫苗
• 去活化口服氧
• O139

第5章 全球霍亂疫苗市場：依產品分類

• 市場分析、洞察與預測
• Vaxchora
• 杜科拉爾
• 尚科爾
• 其他

第6章 全球霍亂疫苗市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 其他

第7章 全球霍亂疫苗市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Valneva SE
  • Sanofi SA
  • Emergent BioSolutions Inc
  • PaxVax Inc
  • EuBiologics Co.Ltd
  • Shantha Biotechnics Limited
  • Hilleman Laboratories
  • Astellas Pharma Inc
  • Incepta Vaccine Ltd
  • Vabiotech

The Cholera Vaccines Market size is expected to reach USD 276.20 Million in 2034 from USD 110.36 Million (2025) growing at a CAGR of 10.73% during 2026-2034.

The cholera vaccines market is advancing as public health authorities prioritize epidemic preparedness and global immunization coverage. Future vaccines will leverage novel oral formulations, thermostable delivery systems, and adjuvant optimization to improve immunogenicity, shelf life, and ease of deployment in remote regions. Integration with digital immunization tracking platforms will enable efficient monitoring of coverage rates and outbreak management.

Emerging technologies, including recombinant vector vaccines and synthetic peptide-based formulations, promise faster production timelines and broader strain coverage. AI-driven epidemiological modeling will guide strategic vaccination campaigns, optimizing resource allocation and reducing disease incidence. Mobile health systems will facilitate community-level vaccine awareness, scheduling, and adherence tracking, supporting public health infrastructure.

Future growth will be fueled by global initiatives targeting waterborne disease prevention, improved supply chain logistics, and policy support for mass vaccination. By combining innovative vaccine technologies, digital health integration, and proactive outbreak management, cholera vaccines will play a critical role in reducing global disease burden and strengthening public health resilience.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Whole Cell v. Cholerae O1 with Recombinant B- subunit
• Killed Oral O1
• O139

By Product

• Vaxchora
• Dukoral
• Shanchol
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Other

COMPANIES PROFILED

• Valneva SE, Sanofi SA, Emergent BioSolutions Inc, PaxVax Inc, EuBiologics Co, Ltd, Shantha Biotechnics Limited, Hilleman Laboratories, Astellas Pharma Inc, Incepta Vaccine Ltd, Vabiotech
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHOLERA VACCINES MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Whole Cell v. Cholerae O1 with Recombinant B- subunit Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Killed Oral O1 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. O139 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL CHOLERA VACCINES MARKET: BY PRODUCT 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Vaxchora Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Dukoral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Shanchol Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL CHOLERA VACCINES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL CHOLERA VACCINES MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.2.1 By Type
  • 7.2.2 By Product
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.3.1 By Type
  • 7.3.2 By Product
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.4.1 By Type
  • 7.4.2 By Product
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.5.1 By Type
  • 7.5.2 By Product
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.6.1 By Type
  • 7.6.2 By Product
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CHOLERA VACCINES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Valneva SE
  • 9.2.2 Sanofi S.A
  • 9.2.3 Emergent BioSolutions Inc
  • 9.2.4 PaxVax Inc
  • 9.2.5 EuBiologics Co.Ltd
  • 9.2.6 Shantha Biotechnics Limited
  • 9.2.7 Hilleman Laboratories
  • 9.2.8 Astellas Pharma Inc
  • 9.2.9 Incepta Vaccine Ltd
  • 9.2.10 Vabiotech